Literature DB >> 15367421

Gemcitabine and haemolytic-uraemic syndrome.

I Ruiz, J Del Valle, A Gómez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15367421     DOI： 10.1093/annonc/mdh397

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.

Authors:  Florence Daviet; Franck Rouby; Pascale Poullin; Julie Moussi-Francès; Marion Sallée; Stéphane Burtey; Julien Mancini; Florence Duffaud; Renaud Sabatier; Bertrand Pourroy; Aurélie Grandvuillemin; Steven Grange; Véronique Frémeaux-Bacchi; Paul Coppo; Joëlle Micallef; Noémie Jourde-Chiche
Journal:  Br J Clin Pharmacol       Date:  2018-12-18       Impact factor: 4.335

2.  The use of eculizumab in gemcitabine induced thrombotic microangiopathy.

Authors:  Vinod Krishnappa; Mohit Gupta; Haikoo Shah; Abhijit Das; Natthavat Tanphaichitr; Robert Novak; Rupesh Raina
Journal:  BMC Nephrol       Date:  2018-01-12       Impact factor: 2.388

3.  Gemcitabine-induced haemolytic uremic syndrome, although infrequent, can it be prevented: A case report and review of literature.

Authors:  Esther U Cidon; Pilar A Martinez; Tamas Hickish
Journal:  World J Clin Cases       Date:  2018-10-26       Impact factor: 1.337
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.